Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development

1 source ·1 article ·Aug 18, 21:26 UTC Psyence Biomedical Ltd.

Company says growing federal commitment to ibogaine aligns directly with the pharmaceutical development and manufacturing platform Psyence BioMed has built NEW YORK, Aug. 18, 2026 (GLOBE NEWSWIRE) — Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyen…

Covered by 1 outlet